Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.76 |
| ▸ | ESRRG | P62508 | 4/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.76 |
| ▸ | ESRRB | O95718 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | TP53 | P04637 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | PGR | P06401 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | PLD2 | O14939 | 1/20 | 0.76 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Miproxifene SCHEMBL34173 | 1.00 | ESR1 (0.76) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL409027 | 1.00 | ESR1 (0.76) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL9857626 | 0.99 | ESR1 (0.74) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL9857619 | 0.99 | ESR1 (0.74) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL9857612 | 0.99 | ESR1 (0.74) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL2128564 | 0.99 | ESR1 (0.74) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL3781209 | 0.94 | ESR1 (0.69) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL430163 | 0.94 | ESR1 (0.69) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL3781215 | 0.94 | ESR1 (0.69) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| SCHEMBL9857240 | 0.91 | ESR1 (0.90) | ESR1ESR2ESRRGMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | SPROUT PHARMACEUTICALS, INC. | 2008-05-01 | — | — | US | claimed |
| EP-1740181-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-10 | — | — | EP | claimed |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | claimed |
| WO-2005102342-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| US-11633382-B2 | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen | PARACRINE THERAPEUTICS AB (SE) | 2023-04-25 | — | — | US | disclosed |
| US-20210186932-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND ANTI-ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2021-06-24 | — | — | US | disclosed |
| US-20200030259-A1 | Antiestrogens and/or Aromatase Inhibitors for Use in Treating Obesity and Related Symptoms | REPROS THERAPEUTICS INC (US) | 2020-01-30 | — | — | US | disclosed |
| EP-2819676-B1 | COMBINATION THERAPY FOR TREATING ANDROGEN DEFICIENCY | REPROS THERAPEUTICS INC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9687458-B2 | Trans-clomiphene for use in cancer therapy | REPROS THERAPEUTICS INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | disclosed |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | VIVUS, INC. | 2004-03-04 | — | — | US | disclosed |
| EP-0677507-B1 | PROCESS FOR PRODUCING ACID-ADDITION SALT OF Z-ISOMER OF TRIPHENYLETHYLENE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 1998-04-08 | — | — | EP | disclosed |
| US-5565611-A | Process for preparing acid addition salt of Z-isomer of triphenylethylene compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-10-15 | — | — | US | disclosed |
| EP-0677507-A1 | PROCESS FOR PRODUCING ACID-ADDITION SALT OF Z-ISOMER OF TRIPHENYLETHYLENE COMPOUND | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1995-10-18 | — | — | EP | disclosed |
| EP-0272330-B1 | 1,1,2-TRIARYL-1-BUTENE DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1991-05-22 | — | — | EP | disclosed |
| US-4897503-A | ANTITUMOR AGENTS; TREATING MAMMARY CANCER AND ANOVULATORY INFERTILITY | TAIHO PHARMACEUTICAL (JP) | 1990-01-30 | — | — | US | disclosed |
| EP-0272330-A1 | 1,1,2-TRIARYL-1-BUTENE DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | ESR1 303/4885ESR2 616/4885ESRRG 1280/4885 |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | ESR1 303/4885ESR2 616/4885ESRRG 1280/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | ESR1 303/4885ESR2 616/4885ESRRG 1280/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | ESR1 303/4885ESR2 616/4885ESRRG 1280/4885 |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | PDE12, PDE3A, PDE2A | ESR1 76/4885ESR2 122/4885ESRRG 227/4885 |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | ESR1 303/4885ESR2 616/4885ESRRG 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.